Pfizer Inc (NYSE:PFE) had a stellar first quarter in terms of profit, which grew by 61% to $7.8 billion on the sales of its COVID-19 vaccine, which reached $13 billion. The company, however, adjusted its earnings per share outlook for this year by 10 cents.
Pfizer’s earnings report
As reported by ABC News, Pfizer expects readjusted earnings of $6.25 to $6.45 per share, down from $6.35 to $6.55 per share. Meanwhile, analysts estimate earnings of $7.14 per share.
The lower earnings guidance is due to rising research and development costs and the strengthening of the U.S. dollar. Still, the company is aiming at $98 billion to $102 billion in total sales this year.
But the pharma giant also had a solid first quarter in terms of revenue, which hit $25 billion or a 77% increase from the same period last year. Refinitiv estimates had pointed to $23.8 billion.
The company said the welcoming quarter results were driven by the sales of booster shots and the development of the vaccine for children.
Vaccine sales outlook
For the year 2022, financial results are bound to rely on Covid vaccine sales. Pfizer has anticipated sales of $32 billion in vaccine sales and $22 billion for Paxlovid, the company’s antiviral treatment.
Chairman and CEO Albert Bourla told analysts Tuesday, “We are seeing strong signs for increasing demand for Paxlovid.”
Pfizer’s Covid shot is at the top of applications in both the U.S. and the European Union, while the company seeks authorization for the three-dose vaccine for under-five-year-olds. Mikael Dolsten, the firm’s chief scientific officer, said Pfizer would submit third-dose data by the end of May or early June.
As reported by The Guardian, a pharma campaigner from Global Justice Now has accused Pfizer of profiteering on the huge sales of its Covid vaccine and treatments.
Tim Bierley said, “Throughout the pandemic, Pfizer has refused to share its technology and know-how. Instead, it has maintained monopoly control over its vaccine and treatment, keeping a chokehold on global supply.”
VALUEWALK LLC is not a registered or licensed investment advisor in any jurisdiction. Nothing on this website or related properties should be considered personalized investments advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. VALUEWALK LLC, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. The Company disclaims any liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.
Recommended content
Editors’ Picks
Gold remains within striking distance of new record-high above $3,300
Gold clings to strong daily gains above $3,300 after setting a new all-time peak near $3,320 earlier in the day. Continued concerns over the escalating US-China trade tensions and a weakening Greenback, support the demand for the metal prior to Powell's speech.
EUR/USD remains consolidative around 1.1350 on firmer US Retail Sales
EUR/USD maintains its daily gains around the 1.1350 region on the back of the resumption of the bearish tone in the Greenback, which showed no reaction to the stronger-than-expected Retail Sales in March. Later in the day, investors are expected to closely follow Fed Chairman Powell’s comments on the economic outlook.
GBP/USD recedes from tops and revisits the 1.3250 zone
GBP/USD extends its positive streak on Wednesday, now coming under some selling pressure around the 1.3250 after earlier multi-month tops around the 1.3300 mark. The daily uptick comes on the back of the weaker US Dollar and easing inflationary pressure in the UK.
Bitcoin stabilizes around $83,000 as China opens trade talks with President Trump’s administration
Bitcoin price stabilizes around $83,500 on Wednesday after facing multiple rejections around the 200-day EMA. Bloomberg reports that China is open to trade talks with President Trump’s administration.
Future-proofing portfolios: A playbook for tariff and recession risks
It does seem like we will be talking tariffs for a while. And if tariffs stay — in some shape or form — even after negotiations, we’ll likely be talking about recession too. Higher input costs, persistent inflation, and tighter monetary policy are already weighing on global growth.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.